Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 2/20 | 0.31 |
| ▸ | CDK8 | P49336 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.30 |
| ▸ | KDR | P35968 | 2/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25293629 | 0.86 | KDR (0.43) | AXLPDGFRAKDRKITFGFR2 | |
| SCHEMBL25793364 | 0.84 | MET (0.34) | DGAT1AXLCCNCCDK8PDGFRA | |
| SCHEMBL25793374 | 0.83 | GRM2 (0.32) | DGAT1NPC1 | |
| SCHEMBL25793369 | 0.83 | GRM2 (0.33) | DGAT1NPC1 | |
| SCHEMBL25793375 | 0.82 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL25793134 | 0.81 | KDR (0.45) | AXLPDGFRAKDRKITFGFR2 | |
| SCHEMBL25793365 | 0.80 | DGAT1 (0.36) | DGAT1AXLKDR | |
| SCHEMBL25793370 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL25793371 | 0.77 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL20437123 | 0.75 | NPC1 (0.37) | DGAT1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | DGAT1 4127/4885AXL 3641/4885NPC1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.